# Fulmz

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/fulmz

- Industry: Healthcare IT
- Headquarters: Guangzhou, China
- Website: www.fulmz.com
- Total disclosed funding: $17M
- Latest round: Series B (Jul 18, 2022)
- Investors on record: 9

## About

Based in Guangzhou, China and established in 2015, Fulmz operates as a biotechnology company that focuses on application of artificial intelligence technology. Daiguo Deng is the CEO and founder of the company. The company completed angel funding in December 2018. The company raised approximately CNY 100 million series A funding from Panda capital, Tongsheng capital in May 2020.

The company provides AI pharmaceutical platform. The company focuses on central nervous system (CNS), autoimmunity and refractory tumors fields. The company adopts AI drug molecular design, AI virtual screening, AI Prediction of ADMET and AI retrosynthetic analysis technologies. The company's product includes drug design platform - Fulmz Drug Studio. The company also provides contract research organization (CRO) services. The company's pipeline includes best-in-class (BIC) and first-in-class (FIC), including FZ002, FZ008 project.

In July 2022, the company will plan to invest in clinical trial, researching and development of product pipeline, constructing platform and team.

## Funding rounds

- Series B, Jul 18, 2022, $1.5M — Panda Capital, Zhengxuan Capital, Kexun Ruijin Capital, Challenjers Venture
- Series A, Nov 12, 2020, $15M — Panda Capital, Jinkong Fund Management, Tong Sheng Capital
- Angel, Dec 1, 2018 — Sinovation Ventures, 01VC, Welight Capital

## Investors

- Sinovation Ventures (https://capitalatlas.ai/funds/sinovation-ventures) — Angel
- 01VC (https://capitalatlas.ai/funds/01vc) — Angel
- Welight Capital (https://capitalatlas.ai/funds/welight-capital) — Angel
- Panda Capital (https://capitalatlas.ai/funds/panda-capital) — Series A, Series B
- Jinkong Fund Management (https://capitalatlas.ai/funds/jinkong-fund-management) — Series A
- Tong Sheng Capital (https://capitalatlas.ai/funds/tong-sheng-capital) — Series A
- Zhengxuan Capital (https://capitalatlas.ai/funds/zhengxuan-capital) — Series B
- Kexun Ruijin Capital (https://capitalatlas.ai/funds/kexun-ruijin-capital) — Series B
- Challenjers Venture (https://capitalatlas.ai/funds/challenjers-venture) — Series B